Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Subcutaneous Itepekimab AI vs PFS in Healthy Participants
NCT06114238Phase 1Completed
- Sponsor
- Sanofi
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of itepekimab in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration at Day 141, Area Under the Concentration-Time Curve from Time Zero to the Last Measurable Concentration at Day 141 and 1 more. Started Sep 2021; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06114238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114238.